Cost-Cutting Measures and Strategic Review Progress
The company has implemented cost-cutting measures, expected to make the fourth quarter EBITDA positive. The strategic review has accelerated, with strong interest in IRIDEX's products and potential transactions expected before year-end.
Positive Outlook for Fourth Quarter
Despite the third-quarter challenges, there's a positive outlook for the fourth quarter with increasing momentum in glaucoma products and promising leads from the American Academy of Ophthalmology meeting.
Revenue Growth in Glaucoma Products
Revenue from the Cyclo G6 product family increased by 3% in the third quarter compared to the previous year.
Improved Glaucoma Reimbursement Landscape
The new LCD reimbursement changes for glaucoma procedures, effective November 17, are expected to increase physician adoption of IRIDEX laser consoles and probes.